| Old Articles: <Older 8611-8620 Newer> |
|---|
 |
Pharmaceutical Executive
June 1, 2013 |
Country Report: Ireland Ireland has been a pharma industry darling since the 1960s, when a then-newly established IDA targeted the sector as a strategic area for development. Today, the numbers are eye catching.   |
Pharmaceutical Executive
June 1, 2013
Julian Upton |
Opening the Patent Box Are the answers to the UK pharma sector's problems to be found in the government's new "Patent Box," which introduces a lower rate of corporation tax on profits generated from UK-owned intellectual property. |
Pharmaceutical Executive
June 1, 2013
Tom Reynolds |
Finding Strategic Levers in the Supply Chain Customer-focused supply-chain capabilities are becoming a more important part of a company's competitive advantage. |
Pharmaceutical Executive
June 1, 2013 |
When Gurus Get It Wrong Despite their high status, management gurus aren't always on point when it comes to pharma, writes John Ansell. |
Pharmaceutical Executive
June 1, 2013
Ben Comer |
From Locked Box to Data Sphere Project Data Sphere aims to liberate clinical trial data sets from industry and academic vaults, in an attempt to catalyze cancer research and discovery. |
Pharmaceutical Executive
June 1, 2013
Michele McGovern |
Pharmacy Compounding: What's Ahead for Manufacturers Compounders are under increased scrutiny following last year's spinal meningitis outbreak. |
Pharmaceutical Executive
June 1, 2013
Jill Wechsler |
Washington Report: Innovation, Coverage, and Costs The backlash against high prices for new medicines will impact research, patent exclusivity, and drug benefits. |
Pharmaceutical Executive
June 1, 2013
William Looney |
Recognizing the Best Getting patients to take their medicine on spec and on time is the challenge that never goes away; it's the deadweight baggage accompanying every industry innovation since the arrival of aspirin a century ago. |
Chemistry World
June 20, 2013
Sarah Houlton |
US supreme court rules genes can't be patented In a long-running case against Myriad Genetics, the court decided the BRCA1 and BRCA2 genes are a 'product of nature, and not patent eligible merely because [they have] been isolated.' |
Chemistry World
June 19, 2013
Laura Howes |
AstraZeneca announce new UK hub The new hub will consolidate all of AZ's UK activities, including biologics arm MedImmune, at the Cambridge Biomedical Campus on the southern outskirts of the city. |
| <Older 8611-8620 Newer> Return to current articles. |
